Global R&D Pipeline
My Favorite
Hot Targets:
IL13
Back
Total number of drugs
47
Phase II and later clinical stages
17%
Involving companies
61
Main therapeutic areas
Immune System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APG333/APG-777 | APG333/APG-777 | Monoclonal antibody | Immune System Diseases Respiratory Diseases | IL-13 inhibitors TSLP inhibitors | Paragon Therapeutics, Inc. | Paragon Therapeutics, Inc. Apogee Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | APG333/APG-777 | - | - | detail > | |
| Dectrekumab | Dectrekumab | Monoclonal antibody | Immune System Diseases Infectious Diseases Digestive System Disorders Hemic and Lymphatic Diseases Otorhinolaryngologic Diseases Respiratory Diseases Skin and Musculoskeletal Diseases Other Diseases | IL-13 inhibitors | Novartis Pharma AG | - | Discontinued (in Phase 2) | - | - | - | - | - | - | - | - | - | Dectrekumab | - | - | detail > | |
| FWB-1313 | FWB-1313 | Monoclonal antibody | Immune System Diseases | IL-13 inhibitors | Shenzhen Fuwo Pharmaceutical Co. Ltd. | - | Discontinued (in Preclinical) | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | FWB-1313 | - | - | detail > | |
| CN118215679 | CN118215679 | Monoclonal antibody | Infectious Diseases Nervous System Diseases Digestive System Disorders Skin and Musculoskeletal Diseases Urogenital Diseases | - | Dermira, Inc. | Dermira, Inc. | Discovery | - | - | - | - | - | - | - | - | - | CN118215679 | - | - | detail > | |
| CN120842236 | CN120842236 | Small molecule drug | Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases Other Diseases | IL-13 inhibitors IL-4 inhibitors IgE inhibitors TNF-α inhibitors TSLP inhibitors | Kunming Medical University | Kunming Medical University | Discovery | - | - | - | - | - | - | - | - | - | CN120842236 | - | - | detail > | |
| WO2024186796 | WO2024186796 | Monoclonal antibody | Nervous System Diseases Skin and Musculoskeletal Diseases | - | Dermira, Inc. | Dermira, Inc. | Discovery | - | - | - | - | - | - | - | - | - | WO2024186796 | - | - | detail > | |
| TSLP x IL-13 (Generate) | TSLP x IL-13 (Generate) | Bispecific antibody | Immune System Diseases Congenital Disorders Skin and Musculoskeletal Diseases | IL-13 inhibitors TSLP inhibitors | Generate Biomedicines, Inc. | Generate Biomedicines, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | TSLP x IL-13 (Generate) | - | - | detail > | |
| APG-222 | APG-222 | Monoclonal antibody | Immune System Diseases Congenital Disorders Skin and Musculoskeletal Diseases | IL-13 inhibitors OX40L inhibitors | Apogee Therapeutics, Inc. | Apogee Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | APG-222 | - | - | detail > | |
| PX-130 | PX-130 | Bispecific antibody | Immune System Diseases Congenital Disorders Skin and Musculoskeletal Diseases | IL-13 inhibitors IL-22 inhibitors | Proteologix US, Inc. | Proteologix US, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | PX-130 | - | - | detail > | |
| BSI-501 | BSI-501 | Bispecific antibody | Immune System Diseases | IL-13 inhibitors IL-4 inhibitors | Biosion, Inc. | - | Discontinued (in Preclinical) | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | BSI-501 | - | - | detail > |
Total 47 data
1
2
3
4
5
